Classes
DEA Class; Rx
Common Brand Names; Anzemet
- Antiemetics, Selective 5-HT3 Antagonist
Description
Oral/intravenous antiemetic; 5-HT3 receptor antagonist
Oral tablet used for prevention of chemotherapy-induced nausea/vomiting; injection used for prevention and treatment of PONV
Risk of dose-dependent QT prolongation and torsades de pointes
Indications
Indicated for prevention and treatment of postoperative nausea and vomiting (PONV)
Contraindications
Hypersensitivity
Coadministration with apomorphine; combination reported to cause profound hypotension and loss of consciousness
IV administration for chemotherapy-induced nausea/vomiting (CINV) because of risk for QT, PR, and QRS prolongation
Adverse Effects
- Headache
- Diarrhea
- Dizziness
- Drowsiness
- Fatigue
- Bradycardia
- HTN
- Hypotension
- Tachycardia
- Abdominal pain
- Dyspepsia
- Abnormal liver function
- Chills
- Fever
- Oliguria
- Urinary retention
- Pain
- Pruritus
Warnings
Patients at risk for prolongation of cardiac conduction intervals, particularly long QTc interval, congenital long QT syndrome, uncorrected hypokalemia or hypomagnesemia, or receiving other QT-prolonging drugs
Serotonin syndrome reported with 5-HT3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs including SSRIs, SNRIs, MAO inhibitors, lithium, tramadol, methylene blue IV, and mirtazapine
Correct hypokalemia and hypomagnesemia before administration
Use electrocardiogram (ECG) monitoring in patients with congestive heart failure, bradycardia, underlying heart disease, renal impairment, or who are elderly
Pregnancy and Lactation
Pregnancy Category: B
Lactation: not known whether distributed into breast milk, use caution
Maximum Dosage
100 mg/dose PO; 12.5 mg/dose IV (for prevention/treatment of post-operative nausea/vomiting). Information on maximum total daily dose is unavailable.
100 mg/dose PO; 12.5 mg/dose IV (for prevention/treatment of post-operative nausea/vomiting). Information on maximum total daily dose is unavailable.
1.8 mg/kg PO (Max: 100 mg/dose) for prevention of chemotherapy-induced nausea/vomiting; 0.35 mg/kg IV (Max: 12.5 mg/dose) for prevention/treatment of post-op nausea/vomiting.
2 years or older: 1.8 mg/kg PO (Max: 100 mg/dose) for prevention of chemotherapy-induced nausea/vomiting; 0.35 mg/kg IV (Max: 12.5 mg/dose) for prevention/treatment of post-op nausea/vomiting.
Younger than 2 years: Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
Dolasetron mesylate
injectable solution
- 20mg/mL
tablet
- 50mg
- 100mg
